clinical trial · NCT07080931
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·phase3·recruiting·n = 294
Androgenetic Alopecia5% minoxidil foamPlacebo for 5% Minoxidil Foam
brief summary
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
started
Feb 24, 2025
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Mar 5, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol